New insider activity at Quoin Pharmaceuticals ( (QNRX) ) has taken place on October 15, 2025.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Director Dennis Langer has made a significant investment in Quoin Pharmaceuticals by purchasing 15,152 shares of the company’s stock, valued at $128,640.
Recent Updates on QNRX stock
In the last 24 hours, Quoin Pharmaceuticals (QNRX) announced a significant private placement agreement with institutional investors to raise up to $104.5 million, which includes an initial $16.6 million. This funding is aimed at supporting the company’s corporate purposes and the development of QRX003 for Netherton Syndrome, and is expected to sustain the company financially until 2027. Despite this positive development, Quoin Pharmaceuticals is facing challenges due to its lack of revenue generation and heavy reliance on external financing. Technical analysis indicates a bearish trend, and valuation metrics reflect the company’s lack of profitability, resulting in a low stock score and significant risks for investors. Trading of QNRX was temporarily halted due to volatility, but has since resumed.
Spark’s Take on QNRX Stock
According to Spark, TipRanks’ AI Analyst, QNRX is a Underperform.
Quoin Pharmaceuticals is in a challenging financial position with no revenue generation and high reliance on external financing. The technical analysis indicates a bearish trend, though some technical indicators suggest the stock may be oversold. Valuation metrics reflect the company’s lack of profitability. The combination of these factors results in a low stock score, highlighting significant risks to investors.
To see Spark’s full report on QNRX stock, click here.
More about Quoin Pharmaceuticals
YTD Price Performance: -38.30%
Average Trading Volume: 285,181
Technical Sentiment Signal: Sell
Current Market Cap: $8.74M